Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes.
Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes.
复制标题
DOI：
10.1007/s12185-008-0119-y
复制
发表时间：
2008-07
影响因子：
2.1
通讯作者：
Ozawa, Keiya
中科院分区：
文献类型：
--
作者：
Suzuki, Takahiro;Tomonaga, Masao;Miyazaki, Yasushi;Nakao, Shinji;Ohyashiki, Kazuma;Matsumura, Itaru;Kohgo, Yutaka;Niitsu, Yoshiro;Kojima, Seiji;Ozawa, Keiya
许多骨髓衰竭综合征患者需要频繁输注红细胞，多数患者最终因铁的过度积累导致器官功能障碍。治疗输血引起的铁超载的唯一方法是铁螯合疗法。然而，大多数患者并没有得到有效的治疗，因为门诊患者很难每天/持续给药去铁胺。最近，一种新型的口服铁螯合剂，去铁氧胺已被开发出来，该药物的引入可能有助于许多患者从铁螯合治疗中获益。在这篇综述中，我们将讨论输血依赖患者铁超载的现状，以及日本铁超载治疗指南的发展，这些指南是由日本特发性骨髓衰竭综合征国家研究小组制定的。
Many patients with bone marrow failure syndromes need frequent transfusions of red blood cells, and most of them eventually suffer from organ dysfunction induced by excessively accumulated iron. The only way to treat transfusion-induced iron overload is iron chelating therapy. However, most patients have not been treated effectively because daily/continuous administration of deferoxamine is difficult for outpatients. Recently, a novel oral iron chelator, deferasirox, has been developed, and introduction of the drug may help many patients benefit from iron chelation therapy. In this review, we will discuss the current status of iron overload in transfusion-dependent patients, and the development of Japanese guidelines for the treatment of iron overload in Japan, which were established by the National Research Group on Idiopathic Bone Marrow Failure Syndromes in Japan.
登录
查看更多内容
影响因子：
3.1
作者：
Di Tucci, Anna Angela;Murru, Roberta;Angelucci, Emanuele
通讯作者：
Angelucci, Emanuele
影响因子：
20.3
作者：
Cappellini, MD;Cohen, A;Alberti, D
通讯作者：
Alberti, D
影响因子：
6.5
作者：
Bowen, D;Culligan, D;Parker, J
通讯作者：
Parker, J
影响因子：
45.3
作者：
Malcovati, L;Della Porta, MG;Cazzola, M
通讯作者：
Cazzola, M
影响因子：
6.5
作者：
Jensen, PD;Heickendorff, L;Ellegaard, J
通讯作者：
Ellegaard, J